MedTrace Logo

Pediatric Disease Registry in Essential Thrombocythaemia (ET)

NCT01198717 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-03-17

No results posted yet for this study

Summary

The aim of this study is to evaluate the progression of ET in children (aged 6-17years inclusive) over a period of 5 years maximum. The study will also assess how children are diagnosed, treatment options for those children with symptoms and events related to their ET and the outcomes of those treatments.

Conditions

  • Essential Thrombocythemia (ET)

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-28
Primary Completion
2016-03-01
Completion
2016-03-01

Countries

  • Czechia
  • France
  • Germany
  • Greece
  • Italy
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01198717 on ClinicalTrials.gov